2024年11月7号,和誉医药(港交所代码:02256)宣布,公司将在2024年欧洲肿瘤内科学会亚洲年会(ESMO Asia Congress 2024)上以口头报告形式展示其自主研发的口服PD-L1抑制剂ABSK043治疗晚期实体瘤患者的最新1期研究结果。此次ESMO亚洲年会将于 2024 年 12 月 6 日至 8 日在新加坡举行。
和誉医药将在本届ESMO Asia 2024 大会上展示以下信息:
报告编号:485
标题:用于治疗晚期实体瘤患者的口服PD-L1抑制剂ABSK043的1期研究最新结果
报告时间:12月6日 10:42AM-10:52 AM
关于ABSK043
ABSK043为一款全新的具备优异活性及高度选择性的口服小分子PD-L1抑制剂。癌细胞可以利用PD-1及其配体PD-L1这些免疫检查点来逃避免疫监管和清除,抑制或限制T细胞应答。ABSK043可与PD-L1受体特异性结合并诱导其从细胞表面内吞,有效地抑制PD-1/PD-L1的相互作用,解除PD-L1介导的T细胞活化抑制作用。ABSK043在多个临床前模型中展现出与已获批PD-L1抗体相当的抗肿瘤功效。截止目前,全球已有多款PD-1/PD-L1抗体药物获批上市,但并无PD-1/PD-L1小分子药物获批。ABSK043目前正在澳大利亚和中国开展针对晚期实体肿瘤的I期临床试验。
Abbisko Therapeutics to present updated results from a phase 1 study of oral PD-L1 inhibitor ABSK043 at ESMO Asia Congress 2024
On November 7, 2024, Abbisko Therapeutics (HKEX: 02256) today announced that it will deliver an oral presentation of updated phase 1 study results on its independently discovered oral PD-L1 inhibitor, ABSK043, in patients with advanced solid tumors at ESMO Asia Congress 2024, taking place from December 6 to 8, 2024 in Singapore.
Abbisko presentations to be held at ESMO Asia 2024:
Presentation Number: 485
Title: Updated Results of Oral PD-L1 Inhibitor ABSK043 in Advanced Solid Tumor Patients (pts) from a Phase 1 Study
Time: December 6, 10:42AM-10:52 AM
About ABSK043
ABSK043 is a novel, orally administered small molecule PD-L1 inhibitor displaying exceptional activity and high selectivity. Tumor cells can exploit immune checkpoints such as PD-1 and its ligand PD-L1 to evade immune detection and clearance, thereby suppressing or restricting T-cell responses. ABSK043 selectively binds to the PD-L1 receptor and induces its internalization from the cell surface, effectively inhibiting the PD-1/PD-L1 interaction and alleviating PD-L1-mediated suppression of T-cell activation. In several preclinical models, ABSK043 has demonstrated anti-tumor efficacy comparable to approved PD-L1 antibody drugs. While several PD-1/PD-L1 monoclonal antibodies have been approved worldwide, there are currently no approved PD-1/PD-L1 small molecule drugs. ABSK043 is currently being studied in an ongoing Phase I clinical trial for advanced solid tumors in Australia and China.
关于和誉
和誉医药(香港联交所代码:02256)是一家立足中国,着眼全球的创新药研发公司。公司的创始人和管理团队拥有多年顶尖跨国药企的研发和管理经验,并参与了多个临床及上市新药的研发。和誉医药专注于肿瘤新药研发,以小分子肿瘤精准治疗和小分子肿瘤免疫治疗药物为核心,着眼病患及医药市场的需求,秉承国际新药开发的理念和标准,致力于开发新颖及高潜力药物靶点的潜在first-in-class或best-in-class创新药物,用于改善中国及全球病人的生活质量。
自2016年成立以来,和誉医药已拥有由16种候选药物组成的产品管线,涵盖肿瘤精准治疗领域以及肿瘤免疫治疗领域。
更多信息,欢迎访问 www.abbisko.com。